PCSK9 and brain injury: For all patients and any dose, there was a significant increased risk of haemorrhagic stroke with statins compared with control and high-dose statins compared with low-dose statins (0.42% vs. 0.36%; RR 1.15; 95% CI: 1.00–1.32). There was not a significant increased risk of haemorrhagic stroke with PCSK9 inhibitors added to maximally tolerated statins compared with maximally tolerated statins alone (0.09% vs. 0.09%; RR 0.93; 95% CI: 0.58–1.51). For statins, but not for PCSK9 inhibitor, risk is magnified in a medication dose-dependent and type of vascular brain injury-dependent manner.